BCL2 and neoplasm: Clinically, combinatorialinhibition of anti-apoptotic BCL-2 family proteins may represent a viable strategyfor resensitization of ABT-199-resistant neoplasms, offering recourse for patientsthat relapse on ABT-199 monotherapy.